Genomed (WAR:GEN) Total Liabilities: zł1.72 Mil (As of Mar. 2026)


WAR:GEN Genomed SA WAR:GEN
74 GF Score
Price zł29.00
GF Value zł37.88
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Total Liabilities?

Genomed WAR:GEN +14.17% 74 Total Liabilities is zł1.72 Mil as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 74/100 and a GF Value™ of zł37.88 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Genomed's Total Liabilities for the quarter that ended in Mar. 2026 was zł1.72 Mil.

Genomed's quarterly Total Liabilities increased from Sep. 2025 (zł1.57 Mil) to Dec. 2025 (zł2.41 Mil) but then declined from Dec. 2025 (zł2.41 Mil) to Mar. 2026 (zł1.72 Mil).

Genomed's annual Total Liabilities declined from Dec. 2023 (zł2.06 Mil) to Dec. 2024 (zł1.68 Mil) but then increased from Dec. 2024 (zł1.68 Mil) to Dec. 2025 (zł2.41 Mil).

Genomed Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genomed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Total Liabilities Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 1.24 2.06 1.68 2.41

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.47 1.57 2.41 1.72
WAR:GEN
74GF Score
Genomed SA WAR:GEN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genomed's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.294+(0+0.028
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.087+0)
=2.41

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=16.526-14.117
=2.41

Genomed's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.354+(0+0.06
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.307+0)
=1.72

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=15.79-14.069
=1.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of zł1.72 Mil mean?
Genomed (WAR:GEN) has a Total Liabilities of zł1.72 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genomed and its competitors.
Is Genomed's Total Liabilities too high?
Genomed's current Total Liabilities is zł1.72 Mil. Overall, Genomed has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Total Liabilities compare to TMO and DHR?
Genomed's Total Liabilities of zł1.72 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genomed and its competitors. Genomed's current Total Liabilities is zł1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł37.88, compared to a current price of zł29.00 — trading 23.4% below its estimated fair value. The current Total Liabilities is zł1.72 Mil. Genomed's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Total Liabilities is zł1.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł29.00 is trading 23.4% below its estimated GF Value™ of zł37.88. GuruFocus considers Genomed to be Modestly Undervalued.

Key valuation signals for WAR:GEN:

  • Total Liabilities: zł1.72 Mil
  • GF Value™: zł37.88 vs. price of zł29.00 (23.4% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
74GF Score

Get the complete analysis for WAR:GEN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł29.00
Price
zł37.88
GF Value